79562-49-5

Usage

Uses

Used in Organic Synthesis:
1,3-difluoro-2-methyl-4-nitrobenzene is used as an intermediate in organic synthesis for the production of various chemical compounds. Its presence of fluorine and nitro groups allows for a range of reactions that can lead to the formation of diverse organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, 1,3-difluoro-2-methyl-4-nitrobenzene is utilized as a key intermediate for the development of new drugs. Its unique structure can be modified to create potential drug candidates with specific therapeutic properties.
Used in Chemical Research:
1,3-difluoro-2-methyl-4-nitrobenzene is also used in chemical research to study the effects of fluorination and nitration on the reactivity and stability of aromatic compounds. This can lead to a better understanding of chemical reactions and the development of new synthetic methods.

InChI:InChI=1/C7H5F2NO2/c1-4-5(8)2-3-6(7(4)9)10(11)12/h2-3H,1H3

Upstream product

• 443-84-5 2,6-difluorotoluene 

Downstream Products

• 1020173-26-5 1-benzyloxy-3-fluoro-2-methyl-4-nitro-benzene 
• 1068604-80-7 C₁₄H₈ClFN₂O₃ 
• 1176335-25-3 cyano-(3-fluoro-2-methyl-4-nitro-phenyl)-acetic acid tert-butyl ester 
• 1020173-27-6 4-amino-3-fluoro-2-methyl-phenol 
• 1020173-28-7 4-(2-chloro-pyridin-4-yloxy)-2-fluoro-3-methyl-phenylamine 
• 1020173-29-8 2-fluoro-3-methyl-4-[2-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yloxy]-phenylamine 
• 485832-96-0 3-fluoro-2-methyl-6-nitroaniline 
• 1393177-52-0 4-fluoro-3-methyl-N₂-phenylbenzene-1,2-diamine 
• 1393177-51-9 (3-fluoro-2-methyl-6-nitrophenyl)phenylamine 
• 76350-70-4 2,4-difluoro-3-methyl-aniline 
• 79562-50-8 2-[(2,4-Difluoro-3-methyl-phenylamino)-methylene]-malonic acid diethyl ester 

Relevant academic research and scientific papers

IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

Compounds of the present invention find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites secondary sites, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, thyroid cancer, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, i.e. diabetic retinopathy and age-related macular degeneration, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, human inflammation, rheumatoid spondylitis, ostero-arthritis, asthma, gouty arthritis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, reperfusion injury, neural trauma, neural ischemia, psoriasis, restenosis, chronic obstructive pulmonary disease, bone resorptive diseases, graft-versus-host reaction, Crohn's disease, ulcerative colitis, inflammatory bowel disease, pyresis, and combinations thereof, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, c-KIT kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, VEGFR kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, PDGFR kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, FLT-3 kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, TIE-2 kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, TRK kinases, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, c-MET kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by a HER kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

IMIDAZOLINYLMETHYL ARYL SULFONAMIDE

This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I:and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for th

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.

Quinoline compound useful as antibacterial agents in warm-blooded animals

A quinoline compound of the formula: STR1 wherein R1 is hydrogen or fluorine. A method of preparing the compound (I) is disclosed. The compound (I) and a pharmaceutically acceptable salt thereof are useful as antimicrobial agents.